ClinicalTrials.gg
CompletedNCT01393899Updated Jan 9, 2017Results posted

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

A Phase 2 interventional study of Placebo and CP-690,550 in Crohn's Disease, sponsored by Pfizer. Completed at 91 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-01-09.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Crohn Disease by Pfizer — none open to participants now, none under way, none of them phase 3. Crohn Disease · Pfizer.

Enrollment
6th of 11
180 · median 180
Started
2012
with 1 other
Phase 2
9 of 17
none open now
Registered
8th of 17
by date

Among the 17 studies in Crohn Disease by Pfizer, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2012, is one of 9 in phase 2, and was the 8th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

None of the 17 studies in Crohn Disease by Pfizer is open now. The open studies under Crohn Disease, anywhere →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Crohn Disease by Pfizer as a file.
02

Study summary

This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease who completed the double-blind induction treatment in Study A3921083 and achieved clinical response-100 and/or clinical remission (CDAI\<150) at Week 8.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • tofacitinib
  • Xeljanz
  • CP-690,550
  • maintenance therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who met study entry criteria, and who completed Week 8 visit of Induction Study A3921083.
  • Subjects who achieve clinical response-100 (reduction in CDAI by 100 points) and/or clinical remission (CDAI\<150) in Study A3921083.
  • Women of must test negative for pregnancy prior to study enrolment.

Exclusion criteria

Exclusion Criteria:

  • Subjects who had major protocol violation (as determined by the Sponsor) in the A3921083 study.
  • Subjects likely to require any type of surgery during the study period.
  • Fecal culture/toxin assay indicating presence of pathogenic infection.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Placebo comparator
    Placebo BID

    Drug: Placebo

  • Experimental
    5mg BID

    Drug: CP-690,550

  • Experimental
    10mg BID

    Drug: CP-690,550

Interventions

  • DrugPlacebo

    oral tablets twice daily

  • oral tablets twice daily

  • oral tablets twice daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinical Response-100 (as Defined by a Decrease in Crohn's Disease Activity Index [CDAI] Score of at Least 100 Points From Baseline) or Clinical Remission (CDAI Score Less Than [<]150) at Week 26

    Clinical response-100 was defined as a reduction in CDAI score of at least 100 points from baseline of the parent A3921083 study. Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of a weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's diary kept while on study. CDAI scores range from 0 to approximately 600, higher score indicates higher disease activity.

    Time frame: Week 26

Secondary outcomes

  1. Percentage of Participants With Clinical Response-100 or Clinical Remission at Weeks 4, 8, 12 and 20

    Clinical response-100 was defined as a reduction in CDAI score of at least 100 points from baseline of the parent A3921083 study. Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

    Time frame: Weeks 4, 8, 12 and 20

  2. Percentage of Participants Achieving Clinical Response-100 at Weeks 4, 8, 12, 20 and 26

    Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

    Time frame: Weeks 4, 8, 12, 20 and 26

  3. Percentage of Participants in Clinical Remission at Weeks 4, 8, 12, 20 and 26

    Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

    Time frame: Weeks 4, 8, 12, 20 and 26

  4. Percentage of Participants in Clinical Remission at Week 4, 8, 12, 20 and 26 Among Participants in Remission at Baseline of Maintenance Study

    Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

    Time frame: Weeks 4, 8, 12, 20 and 26

  5. Percentage of Participants in Sustained Clinical Remission (Defined as Being in Clinical Remission at Both Weeks 20 and 26) in the Maintenance Phase

    Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

    Time frame: Weeks 20 and 26

  6. Percentage of Participants With Sustained Clinical Response-100 (Defined as Having at Least a Clinical Response-100 at Both Weeks 20 and 26 From the A3921083 Baseline) in the Maintenance Phase

    Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

    Time frame: Weeks 20 and 26

  7. CDAI Score by Week

    CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity

    Time frame: Baseline and Weeks 4, 8, 12, 20 and 26

  8. Change From Baseline in CDAI Score by Week

    CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity

    Time frame: Weeks 4, 8, 12, 20 and 26

  9. Kaplan-Meier Estimate of the Rate of Time to Relapse

    Time to relapse was defined as increase in CDAI of more than (\>)100 points from the maintenance phase baseline and a CDAI score of \>220 points, or an increase to or above the baseline CDAI score in A3921083. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

    Time frame: Weeks 4, 8 12, 20 and 26

  10. Percentage of Participants Achieving a Steroid-Free Clinical Remission at Week 26 of the Maintenance Phase - Among Participants on Steroids at A3921084 Baseline

    Clinical remission was a CDAI \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body eight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

    Time frame: Week 26

  11. C-Reactive Protein (CRP) by Week

    The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

    Time frame: Baseline and Weeks 4, 8, 12, 20 and 26

  12. Change From Baseline in CRP by Week

    The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

    Time frame: Weeks 4, 8, 12, 20 and 26

  13. Fecal Calprotectin by Week

    Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation.

    Time frame: Baseline and Weeks 8, 12 and 26

  14. Change From Baseline in Fecal Calprotectin by Week

    Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation.

    Time frame: Weeks 8, 12 and 26

  15. Tofacitinib Plasma Concentration by Nominal Post-Dose Sampling Time and Tofacitinib Dose

    Plasma samples were collected from participants for the determination of tofacitinib concentrations. Only samples from tofacitinib-treated participants were subsequently analyzed. Plasma concentration data are summarized by nominal sample collection times specified in the protocol, and actual sample collection times may be different.

    Time frame: Pre-dose, 20 minutes, 40 minutes, 1 hour and 2 hours post-dose at Weeks 12 and 26/early termination visit

07

Results

Posted Jan 9, 2017

Participant flow

Participant flow — Overall Study
MilestonePlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Started596061
Completed273238
Not completed322823
Withdrew: Study terminated by sponsor101
Withdrew: Other100
Withdrew: Withdrawal by subject221
Withdrew: Lost to follow-up001
Withdrew: Does not meet entrance criteria101
Withdrew: Lack of efficacy262116
Withdrew: Adverse event153

Outcome measures

PrimaryPercentage of Participants With Clinical Response-100 (as Defined by a Decrease in Crohn's Disease Activity Index [CDAI] Score of at Least 100 Points From Baseline) or Clinical Remission (CDAI Score Less Than [<]150) at Week 26

Clinical response-100 was defined as a reduction in CDAI score of at least 100 points from baseline of the parent A3921083 study. Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of a weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's diary kept while on study. CDAI scores range from 0 to approximately 600, higher score indicates higher disease activity.

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Response-100 (as Defined by a Decrease in Crohn's Disease Activity Index [CDAI] Score of at Least 100 Points From Baseline) or Clinical Remission (CDAI Score Less Than [<]150) at Week 26
Percentage of participantsPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Percentage of Participants With Clinical Response-100 (as Defined by a Decrease in Crohn's Disease Activity Index [CDAI] Score of at Least 100 Points From Baseline) or Clinical Remission (CDAI Score Less Than [<]150) at Week 2638.10 (27.94 to 49.16)39.53 (29.39 to 50.46)55.81 (44.92 to 66.28)
Statistical analysis
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 1.44 · 80% CI -12.11 to 14.99
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 17.72 · 80% CI 4.07 to 31.37
SecondaryPercentage of Participants With Clinical Response-100 or Clinical Remission at Weeks 4, 8, 12 and 20

Clinical response-100 was defined as a reduction in CDAI score of at least 100 points from baseline of the parent A3921083 study. Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

Time frame:
Weeks 4, 8, 12 and 20
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Response-100 or Clinical Remission at Weeks 4, 8, 12 and 20
Percentage of participantsPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Week 473.81 (63.16 to 82.62)74.42 (63.96 to 83.05)79.07 (68.98 to 86.96)
Week 866.67 (55.69 to 76.37)67.44 (56.64 to 76.95)58.14 (47.22 to 68.46)
Week 1250.00 (39.12 to 60.88)55.81 (44.92 to 66.28)53.49 (42.64 to 64.08)
Week 2040.48 (30.13 to 51.55)39.53 (29.39 to 50.46)51.16 (40.38 to 61.86)
Statistical analysis
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 0.61 · 80% CI -11.57 to 12.79
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 0.78 · 80% CI -12.29 to 13.84
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 5.81 · 80% CI -8.04 to 19.67
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: -0.94 · 80% CI -14.56 to 12.68
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 5.26 · 80% CI -6.52 to 17.04
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: -8.53 · 80% CI -21.94 to 4.88
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 3.49 · 80% CI -10.40 to 17.37
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 10.69 · 80% CI -3.08 to 24.46
SecondaryPercentage of Participants Achieving Clinical Response-100 at Weeks 4, 8, 12, 20 and 26

Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

Time frame:
Weeks 4, 8, 12, 20 and 26
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Response-100 at Weeks 4, 8, 12, 20 and 26
Percentage of participantsPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Week 473.81 (63.16 to 82.62)72.09 (61.49 to 81.04)76.74 (66.45 to 85.02)
Week 866.67 (55.69 to 76.37)62.79 (51.88 to 72.75)58.14 (47.22 to 68.46)
Week 1250.00 (39.12 to 60.88)55.81 (44.92 to 66.28)51.16 (40.38 to 61.86)
Week 2038.10 (27.94 to 49.16)39.53 (29.39 to 50.46)51.16 (40.38 to 61.86)
Week 2635.71 (25.77 to 46.74)37.21 (27.25 to 48.12)55.81 (44.92 to 66.28)
Statistical analysis
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: -1.72 · 80% CI -14.06 to 10.63
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: -3.88 · 80% CI -17.15 to 9.40
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 5.81 · 80% CI -8.04 to 19.67
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 1.44 · 80% CI -12.11 to 14.99
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 1.50 · 80% CI -11.88 to 14.87
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 2.93 · 80% CI -9.06 to 14.92
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: -8.53 · 80% CI -21.94 to 4.88
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 1.16 · 80% CI -12.74 to 15.06
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 13.07 · 80% CI -0.63 to 26.77
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 20.10 · 80% CI 6.54 to 33.66
SecondaryPercentage of Participants in Clinical Remission at Weeks 4, 8, 12, 20 and 26

Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

Time frame:
Weeks 4, 8, 12, 20 and 26
Reported as:
Number · Percentage of participants
Percentage of Participants in Clinical Remission at Weeks 4, 8, 12, 20 and 26
Percentage of participantsPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Week 452.38 (41.42 to 63.16)55.81 (44.92 to 66.28)58.14 (47.22 to 68.46)
Week 847.62 (36.84 to 58.58)48.84 (38.14 to 59.62)39.53 (29.39 to 50.46)
Week 1233.33 (23.63 to 44.31)46.51 (35.92 to 57.36)34.88 (25.14 to 45.75)
Week 2030.95 (21.52 to 41.84)32.56 (23.05 to 43.36)39.53 (29.39 to 50.46)
Week 2628.57 (19.43 to 39.35)37.21 (27.25 to 48.12)41.86 (31.54 to 52.78)
Statistical analysis
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 3.43 · 80% CI -10.41 to 17.28
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 1.22 · 80% CI -12.67 to 15.11
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 13.18 · 80% CI -0.31 to 26.67
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 1.61 · 80% CI -11.33 to 14.55
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 8.64 · 80% CI -4.36 to 21.64
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 5.76 · 80% CI -8.04 to 19.56
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: -8.08 · 80% CI -21.83 to 5.66
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 1.55 · 80% CI -11.63 to 14.73
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 8.58 · 80% CI -4.64 to 21.81
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 13.29 · 80% CI 0.15 to 26.43
SecondaryPercentage of Participants in Clinical Remission at Week 4, 8, 12, 20 and 26 Among Participants in Remission at Baseline of Maintenance Study

Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

Time frame:
Weeks 4, 8, 12, 20 and 26
Reported as:
Number · Percentage of participants
Percentage of Participants in Clinical Remission at Week 4, 8, 12, 20 and 26 Among Participants in Remission at Baseline of Maintenance Study
Percentage of participantsPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Week 472.00 (57.42 to 83.68)78.57 (65.41 to 88.34)80.77 (67.23 to 90.34)
Week 864.00 (49.20 to 76.97)64.29 (50.42 to 76.50)50.00 (35.93 to 64.07)
Week 1240.00 (26.53 to 54.77)64.29 (50.42 to 76.50)42.31 (28.86 to 56.71)
Week 2036.00 (23.03 to 50.80)42.86 (29.87 to 56.67)46.15 (32.36 to 60.43)
Week 2628.00 (16.32 to 42.58)39.29 (26.65 to 53.16)50.00 (35.93 to 64.07)
Statistical analysis
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 6.57 · 80% CI -8.63 to 21.78
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 0.29 · 80% CI -16.63 to 17.20
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 24.29 · 80% CI 7.19 to 41.38
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 6.86 · 80% CI -10.32 to 24.03
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 11.29 · 80% CI -5.22 to 27.79
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 8.77 · 80% CI -6.41 to 23.95
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: -14.00 · 80% CI -31.59 to 3.59
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 2.31 · 80% CI -15.35 to 19.97
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 10.15 · 80% CI -7.41 to 27.71
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 22.00 · 80% CI 4.96 to 39.04
SecondaryPercentage of Participants in Sustained Clinical Remission (Defined as Being in Clinical Remission at Both Weeks 20 and 26) in the Maintenance Phase

Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

Time frame:
Weeks 20 and 26
Reported as:
Number · Percentage of participants
Percentage of Participants in Sustained Clinical Remission (Defined as Being in Clinical Remission at Both Weeks 20 and 26) in the Maintenance Phase
Percentage of participantsPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Percentage of Participants in Sustained Clinical Remission (Defined as Being in Clinical Remission at Both Weeks 20 and 26) in the Maintenance Phase21.43 (13.37 to 31.71)23.26 (14.98 to 33.55)39.53 (29.39 to 50.46)
Statistical analysis
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 1.83 · 80% CI -9.75 to 13.40
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 18.11 · 80% CI 5.57 to 30.64
SecondaryPercentage of Participants With Sustained Clinical Response-100 (Defined as Having at Least a Clinical Response-100 at Both Weeks 20 and 26 From the A3921083 Baseline) in the Maintenance Phase

Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

Time frame:
Weeks 20 and 26
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Clinical Response-100 (Defined as Having at Least a Clinical Response-100 at Both Weeks 20 and 26 From the A3921083 Baseline) in the Maintenance Phase
Percentage of participantsPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Percentage of Participants With Sustained Clinical Response-100 (Defined as Having at Least a Clinical Response-100 at Both Weeks 20 and 26 From the A3921083 Baseline) in the Maintenance Phase33.33 (23.63 to 44.31)25.58 (16.95 to 36.04)51.16 (40.38 to 61.86)
Statistical analysis
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: -7.75 · 80% CI -20.39 to 4.88
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 17.83 · 80% CI 4.33 to 31.33
SecondaryCDAI Score by Week

CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity

Time frame:
Baseline and Weeks 4, 8, 12, 20 and 26
Reported as:
Mean · Score on a scale
CDAI Score by Week
Score on a scalePlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Baseline135.05 ± 69.83127.23 ± 60.46133.98 ± 63.31
Week 4168.24 ± 103.18133.48 ± 89.94143.45 ± 84.26
Week 8171.87 ± 109.18149.78 ± 99.56165.69 ± 95.46
Week 12181.38 ± 108.68158.56 ± 119.41152.93 ± 82.77
Week 20161.76 ± 91.65151.74 ± 106.09112.32 ± 85.47
Week 26137.05 ± 77.65134.77 ± 80.22110.77 ± 76.30
SecondaryChange From Baseline in CDAI Score by Week

CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity

Time frame:
Weeks 4, 8, 12, 20 and 26
Reported as:
Mean · Score on a scale
Change From Baseline in CDAI Score by Week
Score on a scalePlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Week 433.17 ± 76.415.85 ± 69.5211.02 ± 72.22
Week 839.85 ± 83.6820.32 ± 69.59101.96 ± 101.96
Week 1252.81 ± 113.9132.29 ± 88.3524.07 ± 84.46
Week 2032.44 ± 96.1836.83 ± 90.92-14.36 ± 78.58
Week 261.50 ± 93.9117.36 ± 79.81-16.35 ± 75.65
Statistical analysis
  • Placebo vs Tofacitinib 5 mg BID · Linear mixed-effects model · p = =0.0637 · Adjusted mean difference: -30.26 · 80% CI -51.10 to -9.42Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 5 mg BID · Linear mixed-effects model · p = =0.3054 · Adjusted mean difference: -21.06 · 80% CI -47.43 to 5.31Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 5 mg BID · Linear mixed-effects model · p = =0.1316 · Adjusted mean difference: -42.52 · 80% CI -78.57 to -6.48Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 5 mg BID · Linear mixed-effects model · p = =0.5704 · Adjusted mean dofference: -18.01 · 80% CI -59.01 to 22.99Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 5 mg BID · Linear mixed-effects model · p = =0.8389 · Adjusted mean difference: -6.00 · 80% CI -44.22 to 32.21Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 10 mg BID · Linear mixed-effects model · p = =0.1452 · Adjusted mean difference: -23.56 · 80% CI -44.27 to -2.85Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 10 mg BID · Linear mixed-effects model · p = =0.6399 · Adjusted mean difference: -9.61 · 80% CI -36.03 to 16.81Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 10 mg BID · Linear mixed-effects model · p = =0.1949 · Adjusted mean difference: -37.00 · 80% CI -73.57 to -0.42Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 10 mg BID · Linear mixed-effects model · p = =0.1358 · Adjusted mean difference: -47.74 · 80% CI -88.62 to -6.87Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 10 mg BID · Linear mixed-effects model · p = =0.0890 · Adjusted mean difference: -50.38 · 80% CI -88.03 to -12.72Parameter Type: Adjusted Mean Difference
SecondaryKaplan-Meier Estimate of the Rate of Time to Relapse

Time to relapse was defined as increase in CDAI of more than (\>)100 points from the maintenance phase baseline and a CDAI score of \>220 points, or an increase to or above the baseline CDAI score in A3921083. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

Time frame:
Weeks 4, 8 12, 20 and 26
Reported as:
Number · Percent Probability
Kaplan-Meier Estimate of the Rate of Time to Relapse
Percent ProbabilityPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Week 4 (n=35,38,38)14.58 (8.42 to 22.37)7.14 (3.15 to 13.34)11.63 (6.30 to 18.73)
Week 8 (n=32,35,32)21.90 (14.27 to 30.60)14.47 (8.35 to 22.21)23.51 (15.73 to 32.21)
Week 12 (n=24,30,27)39.18 (29.40 to 48.80)26.69 (18.32 to 35.77)31.09 (22.19 to 40.38)
Week 20 (n=19,22,23)51.85 (41.33 to 61.37)39.11 (29.35 to 48.74)38.95 (29.16 to 48.60)
Week 26 (n=1,1,2)69.59 (48.73 to 83.29)50.69 (38.96 to 61.27)43.31 (32.60 to 53.54)
Statistical analysis
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: -7.44 · 80% CI -16.14 to 1.26
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: -7.43 · 80% CI -18.27 to 3.41
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: -12.48 · 80% CI -25.68 to 0.72
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: -12.73 · 80% CI -26.81 to 1.34
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: -18.90 · 80% CI -39.52 to 1.72
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: -2.96 · 80% CI -12.39 to 6.48
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 1.61 · 80% CI -10.14 to 13.36
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: -8.09 · 80% CI -21.54 to 5.36
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: -12.90 · 80% CI -26.99 to 1.19
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: -26.28 · 80% CI -46.54 to -6.02
SecondaryPercentage of Participants Achieving a Steroid-Free Clinical Remission at Week 26 of the Maintenance Phase - Among Participants on Steroids at A3921084 Baseline

Clinical remission was a CDAI \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body eight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Steroid-Free Clinical Remission at Week 26 of the Maintenance Phase - Among Participants on Steroids at A3921084 Baseline
Percentage of participantsPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Percentage of Participants Achieving a Steroid-Free Clinical Remission at Week 26 of the Maintenance Phase - Among Participants on Steroids at A3921084 Baseline16.67 (4.52 to 38.55)27.27 (10.48 to 51.08)33.33 (17.20 to 53.17)
Statistical analysis
  • Placebo vs Tofacitinib 5 mg BID · Difference in percentage: 10.61 · 80% CI -11.44 to 32.66
  • Placebo vs Tofacitinib 10 mg BID · Difference in percentage: 16.67 · 80% CI -4.15 to 37.49
SecondaryC-Reactive Protein (CRP) by Week

The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

Time frame:
Baseline and Weeks 4, 8, 12, 20 and 26
Reported as:
Mean · milligram per liter (mg/L)
C-Reactive Protein (CRP) by Week
milligram per liter (mg/L)PlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Baseline8.08 ± 13.887.08 ± 10.838.59 ± 16.43
Week 416.08 ± 24.628.04 ± 17.367.62 ± 15.03
Week 815.80 ± 28.988.03 ± 10.867.24 ± 16.48
Week 1215.49 ± 17.808.19 ± 11.755.57 ± 13.52
Week 2015.10 ± 20.3710.07 ± 14.566.52 ± 18.26
Week 2627.70 ± 41.7613.00 ± 13.653.57 ± 3.55
SecondaryChange From Baseline in CRP by Week

The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

Time frame:
Weeks 4, 8, 12, 20 and 26
Reported as:
Mean · milligram per liter (mg/L)
Change From Baseline in CRP by Week
milligram per liter (mg/L)PlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Week 410.66 ± 19.470.84 ± 12.52-0.97 ± 10.81
Week 810.33 ± 24.330.96 ± 9.801.29 ± 7.24
Week 1211.78 ± 17.852.36 ± 12.150.39 ± 3.66
Week 2011.48 ± 19.252.92 ± 14.860.91 ± 6.75
Week 2624.07 ± 40.906.62 ± 13.070.59 ± 3.75
Statistical analysis
  • Placebo vs Tofacitinib 5 mg BID · Linear mixed-effects model · p = <0.0001 · Adjusted mean difference: -0.93 · 95% CI -1.34 to -0.53Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 5 mg BID · Linear mixed-effects model · p = =0.0024 · Adjusted mean difference: -0.76 · 95% CI -1.24 to -0.28Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 5 mg BID · Linear mixed-effects model · p = =0.0044 · Adjusted mean difference: -0.75 · 95% CI -1.26 to -0.24Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 5 mg BID · Linear mixed-effects model · p = =0.0582 · Adjusted mean difference: -0.56 · 95% CI -1.13 to 0.02Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 5 mg BID · Linear mixed-effects model · p = =0.0865 · Adjusted mean difference: -0.61 · 95% CI -1.31 to 0.09Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 10 mg BID · Linear mixed-effects model · p = <0.0001 · Adjusted mean difference: -0.92 · 95% CI -1.32 to -0.52Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 10 mg BID · Linear mixed-effects model · p = =0.0002 · Adjusted mean difference: -0.92 · 95% CI -1.40 to -0.45Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 10 mg BID · Linear mixed-effects model · p = <0.0001 · Adjusted mean difference: -1.23 · 95% CI -1.75 to -0.71Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 10 mg BID · Linear mixed-effects model · p = <0.0001 · Adjusted mean difference: -1.30 · 95% CI -1.87 to -0.74Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 10 mg BID · Linear mixed-effects model · p = <0.0001 · Adjusted mean difference: -1.62 · 95% CI -2.30 to -0.95Parameter Type: Adjusted Mean Difference
SecondaryFecal Calprotectin by Week

Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation.

Time frame:
Baseline and Weeks 8, 12 and 26
Reported as:
Mean · milligrams per kilogram (mg/kg)
Fecal Calprotectin by Week
milligrams per kilogram (mg/kg)PlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Baseline380.43 ± 296.24351.39 ± 290.67399.33 ± 346.98
Week 8440.81 ± 350.71295.39 ± 272.25283.76 ± 304.43
Week 12441.40 ± 336.51351.59 ± 303.08194.00 ± 208.50
Week 26939.11 ± 1037.39500.18 ± 337.83243.76 ± 219.04
SecondaryChange From Baseline in Fecal Calprotectin by Week

Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation.

Time frame:
Weeks 8, 12 and 26
Reported as:
Mean · milligrams per kilogram (mg/kg)
Change From Baseline in Fecal Calprotectin by Week
milligrams per kilogram (mg/kg)PlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Week 869.22 ± 384.35-59.73 ± 216.36-123.95 ± 336.67
Week 12103.55 ± 311.15-1.81 ± 228.24-107.04 ± 259.68
Week 26579.10 ± 870.77154.17 ± 349.49-33.75 ± 204.25
Statistical analysis
  • Placebo vs Tofacitinib 5 mg BID · Linear mixed-effects model · p = =0.0566 · Adjusted mean difference: -0.39 · 95% CI -0.79 to 0.01Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 5 mg BID · Linear mixed-effects model · p = =0.3144 · Adjusted mean difference: -0.21 · 95% CI -0.61 to 0.20Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 5 mg BID · Linear mixed-effects model · p = =0.0434 · Adjusted mean difference: -0.56 · 95% CI -1.10 to -0.02Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 10 mg BID · Linear mixed-effects model · p = =0.0050 · Adjusted mean difference: -0.57 · 95% CI -0.96 to -0.18Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 10 mg BID · Linear mixed-effects model · p = =0.0017 · Adjusted mean difference: -0.66 · 95% CI -1.06 to -0.25Parameter Type: Adjusted Mean Difference
  • Placebo vs Tofacitinib 10 mg BID · Linear mixed-effects model · p = <0.0001 · Adjusted mean difference: -1.20 · 95% CI -1.72 to -0.67Parameter Type: Adjusted Mean Difference
SecondaryTofacitinib Plasma Concentration by Nominal Post-Dose Sampling Time and Tofacitinib Dose

Plasma samples were collected from participants for the determination of tofacitinib concentrations. Only samples from tofacitinib-treated participants were subsequently analyzed. Plasma concentration data are summarized by nominal sample collection times specified in the protocol, and actual sample collection times may be different.

Time frame:
Pre-dose, 20 minutes, 40 minutes, 1 hour and 2 hours post-dose at Weeks 12 and 26/early termination visit
Reported as:
Mean · nanograms per milliliter (ng/mL)
Tofacitinib Plasma Concentration by Nominal Post-Dose Sampling Time and Tofacitinib Dose
nanograms per milliliter (ng/mL)Tofacitinib 5 mg BIDTofacitinib 10 mg BID
Week 12, 0 hours (n=43, 40)6.059 ± 7.42646.832 ± 5.7271
Week 12, 20 minutes (n=45, 40)31.56 ± 21.90458.53 ± 53.579
Week 12, 40 minutes (n=47, 41)47.05 ± 23.90485.23 ± 43.726
Week 12, 1 hour (n=46, 42)46.84 ± 20.36582.08 ± 33.779
Week 12, 2 hour (n=44, 42)36.52 ± 14.81069.79 ± 23.274
Week 26/ET, 0 hours (n=43, 46)6.183 ± 13.6739.510 ± 17.115
Week 26/ET, 20 minutes (n=45, 48)40.98 ± 31.71360.48 ± 51.084
Week 26/ET, 40 minutes (n=46, 48)55.83 ± 44.42185.66 ± 37.983
Week 26/ET, 1 hour (n=45, 48)52.59 ± 42.29186.25 ± 30.948
Week 26/ET, 2 hours (n=44, 48)39.09 ± 22.60664.15 ± 23.499

Adverse events

Collected over SAEs were assessed from informed consent through and including 28 calendar days after last administration of study treatment (30 weeks). Non-SAEs were recorded from time of first dose of study treatment through last participant visit (30 weeks).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—7/59 (11.9%)28/59 (47.5%)
Tofacitinib 5 mg BID—6/60 (10%)40/60 (66.7%)
Tofacitinib 10 mg BID—8/61 (13.1%)35/61 (57.4%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Crohn's diseaseGastrointestinal disorders3/590/602/61
AnaemiaBlood and lymphatic system disorders1/590/600/61
Gastrooesophageal reflux diseaseGastrointestinal disorders1/590/600/61
Cholecystitis acuteHepatobiliary disorders1/590/600/61
Abortion inducedSurgical and medical procedures1/590/600/61
Intestinal obstructionGastrointestinal disorders0/591/600/61
Large intestine perforationGastrointestinal disorders0/591/600/61
Anal abscessInfections and infestations0/591/601/61
Clostridium difficile colitisInfections and infestations0/591/600/61
Clostridium difficile infectionInfections and infestations0/591/600/61
Most frequent other events
Showing 10 of 46
Most frequent other events
EventPlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BID
Crohn's diseaseGastrointestinal disorders10/5911/607/61
NasopharyngitisInfections and infestations4/5911/605/61
Urinary tract infectionInfections and infestations4/596/608/61
ArthralgiaMusculoskeletal and connective tissue disorders2/596/604/61
Abdominal painGastrointestinal disorders2/595/604/61
InfluenzaInfections and infestations2/595/603/61
AnaemiaBlood and lymphatic system disorders0/593/605/61
DiarrhoeaGastrointestinal disorders0/593/605/61
HeadacheNervous system disorders2/594/602/61
PyrexiaGeneral disorders2/592/604/61

Baseline characteristics

The safety analysis set consisted of all participants who received at least 1 dose of study medication in this study.

Age, Customized
Age, Customized(Participants)PlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDTotal
Less than or equal to (<=)18 years0000
Between 18 and 44 years344440118
Between 45 and 64 years23152058
More than or equal to (>=)65 years2114
Gender
Gender(Participants)PlaceboTofacitinib 5 mg BIDTofacitinib 10 mg BIDTotal
Female32302486
Male27303794
08

Study locations

91 sites
  • ACMG Endoscopy Center
    Anaheim, California 92801, United States
  • ACRI - Phase I, LLC
    Anaheim, California 92801, United States
  • Advanced Clinical Research Institute-Phase 1, LLC
    Anaheim, California 92801, United States
  • West Coast Clinical Trials
    Cypress, California 90630, United States
  • Alliance Clinical Research
    Oceanside, California 92056, United States
  • Clinical Research Of The Rockies
    Lafayette, Colorado 80026, United States
  • Gasteroenterology Consultants of Clearwater
    Clearwater, Florida 33756, United States
  • West Coast Endoscopy Center
    Clearwater, Florida 33756, United States
  • Clinical Research of West Florida, Inc.
    Clearwater, Florida 33765, United States
  • Shands Endoscopy Center
    Gainesville, Florida 32608, United States
  • Shands Hospital at the University of Florida
    Gainesville, Florida 32610-0214, United States
  • Shands Medical Plaza and Cancer Center
    Gainesville, Florida 32610, United States
  • University of Florida - College of Medicine
    Gainsville, Florida 32610, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • Gulfshore Endoscopy Center (Endoscopies Only)
    Naples, Florida 34102, United States
  • North Florida Gastroenterology Research, LLC
    Orange Park, Florida 32073, United States
  • Internal Medicine Specialists
    Orlando, Florida 32806, United States
  • Gastroenterology Associates of Central Georgia, LLC
    Macon, Georgia 31201, United States
  • Cotton-O'Neil Clinical Research Center, Digestive Health
    Topeka, Kansas 66606, United States
  • Chevy Chase Endoscopy Center
    Chevy Chase, Maryland 20815, United States
  • Metropolitan Gastroenterology Group, PC
    Chevy Chase, Maryland 20815, United States
  • East Ann Arbor Health and Geriatrics Center
    Ann Arbor, Michigan 48109-2701, United States
  • University of Michigan Health Systems
    Ann Arbor, Michigan 48109-5000, United States
  • Center for Digestive Health
    Troy, Michigan 48098, United States
  • Surgical Centers of Michigan
    Troy, Michigan 48098, United States
  • NYU Langone Nassau Gastroenterology Associates
    Great Neck, New York 11021, United States
  • Premier Medical Group of the Hudson Valley, PC
    Poughkeepsie, New York 12601, United States
  • Investigational Drug Services - University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Great Lakes Gastroenterology
    Mentor, Ohio 44060, United States
  • Digestive Health Specialists of Tyler
    Tyler, Texas 75701, United States
  • Endoscopy Center of Tyler
    Tyler, Texas 75701, United States
  • University of Utah HSC
    Salt Lake City, Utah 84132, United States
  • Cardiology Consultants
    Norfolk, Virginia 23502, United States
  • Digestive & Liver Desease Specialists
    Norfolk, Virginia 23502, United States
  • Metropolitan Gastroenterology Group, P C
    Washington DC, Virginia 20006, United States
  • The Center for Digestive Health
    Milwaukee, Wisconsin 53215, United States
  • Wisconsin Center for Advanced Research - GI Associates, LLC
    Milwaukee, Wisconsin 53215, United States
  • Allegiance Research Specialists
    Wauwatosa, Wisconsin 53226, United States
  • GI Associates
    Wauwatosa, Wisconsin 53226, United States
  • Nepean Public Hospital
    Kingswood, New South Wales 2747, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Royal Melbourne Hospital
    Melbourne, 3050, Australia
  • AKH Wien Universitaetsklinik fuer Innere Medizin III
    Wien, 1090, Austria
  • 4 MBAL Parvo vatreshno otdelenie
    Sofia, 1000, Bulgaria
  • MBAL Sofiamed OOD, Otdelenie po gastroenterologia
    Sofia, 1797, Bulgaria
  • Office of Dr. David C. Pearson
    Victoria, British Columbia V8R 6R3, Canada
  • Office of Drs. Ranjith Andrew Singh and Jamie D. Papp,
    Victoria, British Columbia V8V 3P9, Canada
  • PerCuro Clinical Research Ltd.
    Victoria, British Columbia V8V 3P9, Canada
  • London Health Sciences Centre - University Hospital
    London, Ontario N6A 5A5, Canada
  • Montreal General Hospital - McGill University Health Centre
    Montreal, Quebec H3G1A4, Canada
  • Hepato-Gastroenterologie HK, s.r.o.
    Hradec Kralove, 50012, Czech Republic
  • RDG centrum s.r.o. (Radiology only)
    Hradec Kralove, 50012, Czech Republic
  • Medial Pharma spol.s.r.o. (Pharmacy only)
    Hradec Králové, 50012, Czech Republic
  • Hopital Huriez CHRU de Lille
    Lille Cedex, 59037, France
  • Hôpital Haut-Lévêque/Service d hépato-gastroentérologie
    Pessac Cedex, 33064, France
  • Charite - Campus Berlin Mitte
    Berlin, 10117, Germany
  • Charite - Campus Benjamin Franklin
    Berlin, 12200, Germany
  • Charite, Universitaetsmedizin Berlin, Campus Virchow-Klinikum
    Berlin, 13353, Germany
  • Universitaetsklinikum Schleswig-Holstein
    Kiel, 24105, Germany
  • Universitaetsklinikum Ulm, Klinik Fuer Innere Medizin I
    Ulm, 89081, Germany
  • General Hospital of Athens "Evangelismos",1st Gastroenterology Department
    Kolonaki Athens, 106 76, Greece
  • Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak/I. Belgyogyaszat es Gastroenterologia
    Budapest, 1125, Hungary
  • Pannonia Magánorvosi Centrum Kft
    Budapest, 1136, Hungary
  • Laboratorium Kft. Fovarosi és Pest Megyei Mikrobiologiai Laboratorium
    Budapest, H-1044, Hungary
  • Peterfy Sandor Utcai Korhaz, Rendelointezet es Baleseti Kozpont, I. sz. Belgyogyaszat
    Budapest, H-1076, Hungary
  • Bugat Pal Korhaz Egeszsegugyi Szolgaltato Kozhasznu Nonprofit Kft.,
    Gyongyos, 3200, Hungary
  • Laboratórium Kft. Somogy Megyei Mikrobiológiai Laboratórium
    Kaposvár, H-7400, Hungary
  • Clinfan Kft.
    Szekszard, 7100, Hungary
  • Digestive Disease Institute
    Jerusalem, 91031, Israel
  • Meir Medical Center
    Kfar Saba, 44281, Israel
  • Tel Aviv Sourasky Medical Center
    Tel -Aviv, 64932, Israel
  • The Hospital of Hyogo College of Medicine
    Nishinomiya, Hyogo 663-8501, Japan
  • National Hospital Organization Sendai Medical Center
    Sendai, Miyagi 983-8520, Japan
  • Toho University Sakura Medical Center
    Chiba, 285-8741, Japan
  • Hokkaido P.W.F.A.C Sapporo-Kosei general Hospital
    Hokkaido, 060-0033, Japan
  • Osaka City University Hospital
    Osaka, 545-8586, Japan
  • Severance Hospital, Yonsei University Health System
    Seoul, 120-752, Korea, Republic of
  • Samsung Medical Center, Division of Gastroenterology, Department of Internal Medicine
    Seoul, 135-710, Korea, Republic of
  • ASAN Medical Center,Division of Gastroenterology,Department of Internal Medicine
    Seoul, 138-736, Korea, Republic of
  • VU University Medical Center
    Amsterdam, 1081HV, Netherlands
  • Academisch Medisch Centrum
    Amsterdam, 1105 AZ, Netherlands
  • Kingsbury Hospital
    Cape Town, Western Cape 7708, South Africa
  • Parklands Medical Centre
    Durban, 4091, South Africa
  • Comite Etico de Investigacion Clinica
    Barcelona, 08036, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario de La Princesa
    Madrid, 28006, Spain
  • Donetsk National Medical University n.a M. Gorky, Faculty of Internal Medicine #2
    Donetsk, 83017, Ukraine
  • Municipal Institution "Odesa Regional Clinical Hospital", Odesa Regional Centre of Gastroenterology.
    Odesa, 65117, Ukraine
  • Medical Clinical Research Center of Medical Center "Health Clinic" LLC
    Vinnitsa, 21029, Ukraine
09

References and documents

Publications

  • Panes J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017 Jun;66(6):1049-1059. doi: 10.1136/gutjnl-2016-312735. Epub 2017 Feb 16. PubMed 28209624 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2011
First posted
Jul 13, 2011
Start
Mar 2012
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Results first posted
Jan 9, 2017
Last update
Jan 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01393899
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 13, 2011
Start date
Mar 2012
Primary completion
Jul 2015
Completion
Jul 2015
Results posted
Jan 9, 2017
Last update
Jan 9, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion